Effects of intestinal CYP3A4 and P-glycoprotein on oral drug absorption - Theoretical approach

被引:112
|
作者
Ito, K
Kusuhara, H
Sugiyama, Y
机构
[1] Univ Tokyo, Grad Sch Pharmaceut Sci, Bunkyo Ku, Tokyo 1130033, Japan
[2] Kitasato Univ, Sch Pharmaceut Sci, Minato Ku, Tokyo 1088641, Japan
关键词
oral absorption; CYP3A4; P-glycoprotein; diffusion model; drug interaction;
D O I
10.1023/A:1018872207437
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Purpose. To evaluate the effects of gut metabolism and efflux on drug absorption by simulation studies using a pharmacokinetic model involving diffusion in epithelial cells. Methods. A pharmacokinetic model for drug absorption was constructed including metabolism by CYP3A4 inside the epithelial cells, P-gp-mediated efflux into the lumen, intracellular diffusion from the luminal side to the basal side, and subsequent permeation through the basal membrane. Partial differential equations were solved to yield an equation for the fraction absorbed from gut to the blood. Effects of inhibition of CYP3A4 and/or P-gp on the fraction absorbed were simulated for a hypothetical substrate for both CYP3A4 and P-gp. Results. The fraction absorbed after oral administration was shown to increase following inhibition of P-gp. This increase was more marked when the efflux clearance of the drug was greater than the sum of the metabolic and absorption clearances and when the intracellular diffusion constant was small. Furthermore, it was demonstrated that the fraction absorbed was synergistically elevated by simultaneous inhibition of both CYP3A4 and P-gp. Conclusions. The analysis using our present diffusion model is expected to allow the prediction of in vivo intestinal drug absorption and related drug interactions from in vitro studies using human intestinal microsomes, gut epithelial cells, CYP3A4-expressed Caco-2 cells, etc.
引用
收藏
页码:225 / 231
页数:7
相关论文
共 50 条
  • [41] Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine
    Cheng Li
    Dong-Hyun Choi
    Jun-Shik Choi
    Journal of Pharmacokinetics and Pharmacodynamics, 2012, 39 : 99 - 108
  • [42] Effects of efonidipine on the pharmacokinetics and pharmacodynamics of repaglinide: possible role of CYP3A4 and P-glycoprotein inhibition by efonidipine
    Li, Cheng
    Choi, Dong-Hyun
    Choi, Jun-Shik
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2012, 39 (01) : 99 - 108
  • [43] Effects of Curcumin on the Pharmacokinetics of Loratadine in Rats: Possible Role of CYP3A4 and P-glycoprotein Inhibition by Curcumin
    Li, Cheng
    Choi, Byung-Chul
    Kim, Dong-Ki
    Choi, Jun-Shik
    BIOMOLECULES & THERAPEUTICS, 2011, 19 (03) : 364 - 370
  • [44] Effects of nifedipine on the pharmacokinetics of repaglinide in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine
    Jin-Seok Choi
    In Choi
    Dong-Hyun Choi
    Pharmacological Reports, 2013, 65 : 1422 - 1430
  • [45] Effects of nifedipine on the pharmacokinetics of repaglinide in rats: Possible role of CYP3A4 and P-glycoprotein inhibition by nifedipine
    Choi, Jin-Seok
    Choi, In
    Choi, Dong-Hyun
    PHARMACOLOGICAL REPORTS, 2013, 65 (05) : 1422 - 1430
  • [46] INHIBITION OF INTESTINAL P-GLYCOPROTEIN AND EFFECTS ON ETOPOSIDE ABSORPTION
    LEU, BL
    HUANG, JD
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1995, 35 (05) : 432 - 436
  • [47] Proximal Roux-en-Y Gastric Bypass Alters Drug Absorption Pattern But Not Systemic Exposure of CYP3A4 and P-glycoprotein Substrates
    Chan, Lingtak-Neander
    Lin, Yvonne S.
    Tay-Sontheimer, Jessica C.
    Trawick, Dorothy
    Oelschlager, Brant K.
    Flum, David R.
    Patton, Kristen K.
    Shen, Danny D.
    Horn, John R.
    PHARMACOTHERAPY, 2015, 35 (04): : 361 - 369
  • [48] P-glycoprotein (P-gp) plays a significant role in enhancing intestinal metabolism by cytochrome P450 3A4 (CYP3A4)
    Cummins, CL
    Benet, LZ
    FASEB JOURNAL, 2001, 15 (04): : A548 - A548
  • [49] St. John's wort induces intestinal and hepatic CYP3A4 and P-glycoprotein in healthy volunteers.
    Dresser, GK
    Schwarz, UI
    Wilkinson, GR
    Kim, RB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P23 - P23
  • [50] Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4
    Bhardwaj, RK
    Glaeser, H
    Becquemont, L
    Klotz, U
    Gupta, SK
    Fromm, MF
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 302 (02): : 645 - 650